Drugs / Itepekimab
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06114238 | Sep 2021 → Mar 2022 | chronic obstructive pulmonary disease | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03112577 | Jun 2017 → Mar 2019 | allergic asthma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02999711 | Feb 2017 → Aug 2018 | asthma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02958436 | Aug 2016 → Jun 2017 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06691113 | Dec 2024 → Mar 2026 overdue | chronic rhinosinusitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06280391 | Feb 2024 → Sep 2025 | bronchiectasis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT05326412 | May 2022 → Mar 2025 | chronic obstructive pulmonary disease | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT03738423 | Nov 2018 → Mar 2020 | atopic eczema | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03736967 | Nov 2018 → Mar 2020 | atopic eczema | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03546907 | Jul 2018 → Oct 2019 | chronic obstructive pulmonary disease | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT03387852 | Mar 2018 → Mar 2019 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07484230 | May 2026 → Oct 2027 expected | chronic rhinosinusitis | Sanofi | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07424144 | Mar 2026 → Dec 2028 expected | chronic rhinosinusitis | Sanofi | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06834347 | Feb 2025 → Oct 2026 expected | chronic rhinosinusitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06834360 | Feb 2025 → Nov 2026 expected | chronic rhinosinusitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06208306 | Jan 2024 → Dec 2026 expected | chronic obstructive pulmonary disease | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04751487 | Feb 2021 → Apr 2025 | chronic obstructive pulmonary disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04701983 | Dec 2020 → Apr 2025 | chronic obstructive pulmonary disease | Sanofi | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | Sanofi | Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies sanofi.com ↗ |
| 2025-05-30 | Regeneron Pharmaceuticals | Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials regeneron.com ↗ |
| 2024-08-26 | Regeneron Pharmaceuticals | Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases regeneron.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Itepekimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06280391 ↗ |
| Known as | REGN3500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02958436 ↗ |
| Known as | SAR440340 | “Drug: Itepekimab (SAR440340)” NCT06834347 ↗9“Itepekimab (SAR440340)” NCT07424144 ↗ “Itepekimab (SAR440340)” NCT07484230 ↗ “Itepekimab (SAR440340)” NCT06834360 ↗ “Itepekimab (SAR440340)” NCT06280391 ↗ “Itepekimab (SAR440340)” NCT06691113 ↗ “Itepekimab (SAR440340)” NCT06208306 ↗ “Itepekimab SAR440340” NCT04751487 ↗ |
| Action | Inhibit | “Itepekimab (Anti-IL-33 mAb)” NCT04701983 ↗ |
| Modality | Monoclonal antibody | “Itepekimab (Anti-IL-33 mAb)” NCT04701983 ↗ |
| Route | Intravenous | “Intravenous (IV) use” NCT03112577 ↗ |
| Target | IL33 | “Itepekimab (Anti-IL-33 mAb)” NCT04701983 ↗ |